Rise In Demand For Cell And Genetic Therapy Fuels Biologics CDMO Market Growth Driver: Leading Transformation in the Biologics CDMO Market in 2025

What combination of drivers is leading to accelerated growth in the biologics cdmo market?
The increasing need for cellular and genetic therapies is forecasted to fuel the expansion of the biologic CDMO market. These innovative medical treatments employ living cells or genetic components to tackle root disease problems at the cellular or genetic level, offering potential therapies for ailments that are hard to control or incurable using conventional pharmaceuticals. The push for these cell and gene therapies is growing given their potential to provide ground-breaking treatments by dealing with basic genetic or cellular causes. Biologic CDMOs are proficient in managing living cells, viral vectors, and genetic components, ensuring secure and proficient creation of cell and gene therapies. They aid biopharmaceutical firms in overseeing regulatory stipulations and technical issues, thereby aiding in the transition from research to clinical application. For instance, in January 2023, The American Society of Gene & Cell Therapy (ASGCT) recorded a 7% growth in the gene, cell, and RNA therapy pipeline in 2022, amounting to a total of 3,726 therapies under development. Out of these, 55% are gene therapies, 22% are non-genetically altered cell therapies, and 23% are RNA therapies. Consequently, the escalating demand for cell and genetic therapy is accelerating the expansion of the biologic CDMO market.

Get Your Biologics CDMO Market Report Here:
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

What is the projected compound annual growth rate (CAGR) of the biologics cdmo market from 2025 to 2034, and what factors influence it?
The market size of biologics CDMO has experienced rapid growth in the past few years. It is projected to expand from $21.3 billion in 2024 to $24.37 billion in 2025, with a compound annual growth rate (CAGR) of 14.4%. The previous growth can be associated with the surge in biologics development, the efficiency and flexibility of cost, emphasis on central competencies, adherence to regulations and quality assurance, and the global expansion of pharmaceutical supply chains.

There is an anticipation for a swift expansion in the size of the biologics cdmo market in the coming years, with a projected value estimated at $42.33 billion in 2029, representing a compound annual growth rate (CAGR) of 14.8%. The surge in the projected timeline can be linked to factors such as rising demand for biologic therapies, the introduction of biosimilars and biobetters, funds input into biomanufacturing infrastructure, a shift towards delegating complex procedures, an emphasis on a resilient supply chain and risk reduction, regulatory standardization, and fast-tracked approvals. Key trends expected during the forecast period comprise the broadening of abilities to deliver comprehensive solutions, the adoption of single-use technologies, the incorporation of continuous production processes, and the rise of specialized CDMOs.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What trends are poised to drive the future success of the biologics cdmo market?
Leading corporations involved in the biologics CDMO market are introducing technologically progressive solutions like new cell lines to boost the effectiveness and capabilities of biopharmaceutical development and manufacturing. The implemented technology facilitates the production of therapeutic antibodies with increased potency, consequently tackling obstacles in immunotherapy research and development. For example, in November 2023, Lonza Group, a manufacturing corporation based in Switzerland and specializes in pharmaceutical and biotechnology sectors, introduced the GS Effex cell lines. This development is meant to generate antibodies devoid of fucose, a type of sugar molecule, thereby demonstrating heightened potency without sacrificing any other performance aspects. This contributes to resolving issues in immunotherapy research and development linked to the necessity for amplified therapeutic antibodies. This stable, scalable, and productive cell line provides an appropriate means for therapeutic development ranging from discovery-stage research to commercial manufacturing.

What are the major segments of the biologics cdmo market and their role in driving growth?
The biologics cdmo market covered in this report is segmented -

1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars

Subsegments:
1) By Mammalian: Chinese Hamster ovary* (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14056

Which regions are key players in the growth of the biologics cdmo market?
North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the biologics cdmo market?
Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Is Covered In The Biologics CDMO Global Market Report?

• Market Size Forecast: Examine the biologics cdmo market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the biologics cdmo market for a structured understanding.
• Key Players Overview: Analyze major players in the biologics cdmo market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the biologics cdmo market.
• Segment Contributions: Evaluate how different segments drive overall growth in the biologics cdmo market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the biologics cdmo market.
• Industry Challenges: Identify potential risks and obstacles affecting the biologics cdmo market.
• Competitive Landscape: Review strategic developments in the biologics cdmo market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.